Part­ner­ing talks led to Bio­gen’s $800M Night­star buy­out as play­ers clus­tered around the hot deal ta­ble for gene ther­a­pies

Any­one look­ing for some in­sight in­to just how hot gene ther­a­pies have be­come should turn their at­ten­tion to­day to the be­hind-the-scenes ne­go­ti­a­tions that went in­to Bio­gen’s $800 mil­lion deal to buy Night­star Ther­a­peu­tics $NITE.

David Fel­lows, Night­star CEO

Over a pe­ri­od of 7 months, they held buy­out and part­ner­ing talks with 4 dif­fer­ent com­pa­nies be­fore Bio­gen $BI­IB emerged as the win­ner — or at least the last one at the ta­ble talk­ing M&A. Dur­ing that time, Night­star would paint a va­ri­ety of po­ten­tial fu­tures for it­self, topped by a bull ar­gu­ment that it could nail a $1.1 bil­lion prof­it on $1.2 bil­lion in sales come 2025.

The Night­star ac­qui­si­tion came just weeks af­ter Roche com­plet­ed its deal for Spark Ther­a­peu­tics, the US pi­o­neer in high-priced gene ther­a­pies and an­oth­er prime ex­am­ple that main­stream play­ers are in­creas­ing­ly ready to buy up gene ther­a­py as­sets in the clin­ic.

The prof­it fore­casts help tell the sto­ry.

Even on­ly a mod­er­ate suc­cess in Night­star’s books, ac­cord­ing to the proxy, would be close to $650 mil­lion at the peak, with $608 mil­lion in gross prof­it. And a bear case (which in­cludes mar­ket­ing ap­proval) scraped around the $400 mil­lion lev­el for sales and prof­its.

Even be­fore their IPO in the fall of 2017, a new SEC fil­ing re­veals, Bio­gen and a cou­ple of oth­er play­ers in the in­dus­try had been by to kick the tires and dis­cuss strate­gic part­ner­ing am­bi­tions with the ex­ec­u­tive team at Night­star. Those talks were pri­mar­i­ly about li­cens­ing NSR-REP1. Then in the sum­mer of last year things be­gan to heat up when CEO David Fel­lows field­ed a call from Par­ty A look­ing to do some due dili­gence on NSR-REP1 for choroi­deremia.

It was time to spread the word.

A few weeks lat­er, Night­star CFO Senthil Sun­daram had a sit-down with Bio­gen VP Daniel Karp to dis­cuss their mu­tu­al in­ter­est in gene ther­a­pies. Then David Mott, a gen­er­al part­ner at NEA and mem­ber of the board, was chat­ting about “gen­er­al strate­gic top­ics” when he picked up a sig­nal from a cer­tain Par­ty B that they had an in­ter­est in the port­fo­lio. Two months lat­er, yet an­oth­er group stepped up to dis­cuss oph­thal­mol­o­gy gene ther­a­py.

The first hard of­fer came in De­cem­ber, when Par­ty B an­ted up $20.50 a share — a 70% pre­mi­um over its price at the time. And with­in a few weeks Bio­gen, B and C were all giv­en the key to the elec­tron­ic da­ta room. Bio­gen fol­lowed up with a round of­fer of $19 to $21 a share, which opened the door on a sec­ond da­ta vault, even though they said it was still too low.

By ear­ly Feb­ru­ary, though, A, B and C were all on the out­side look­ing in, talk­ing about a col­lab­o­ra­tion in­stead. Bio­gen stuck with the buy­out talks, and came up with $25 a share.

How about $26.50, Night­star coun­tered. 

Bio­gen, though, would on­ly move to $25.50 on March 2. They closed the deal March 4.

Im­age: AP

Elias Zerhouni (Photo by Vincent Isore/IP3/Getty Images)

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

Elias Zerhouni favors blunt talk, and in a recent discussion with NPR, the ex-Sanofi R&D and ex-NIH chief had some tough points to make regarding the pandemic response.

Rather than interpret them, I thought it would be best to provide snippets straight from the interview.

On the Trump administration response:

It was basically amateur hour. There is no central concept of operations for preparedness, for pandemics, period. This administration doesn’t want to or has no concept of what it takes to protect the American people and the world because it is codependent. You can’t close your borders and say, “OK, we’re going to be safe.” You’re not going to be able to do that in this world. So it’s a lack of vision, basically just a lack of understanding, of what it takes to protect the American people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

George Yancopoulos (Regeneron)

Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school com­mence­ment. It didn’t go well

Typically, the commencement speech at Yorktown Central School District in Westchester — like most high schools — is an opportunity to encourage students to face the future with confidence and hope. Regeneron president and co-founder George Yancopoulos, though, went a different route.

In a fiery speech, the outspoken billionaire defended the police against the “prejudice and bias against law enforcement” that has erupted around the country in street protests from coast to coast. And for many who attended the commencement, Yancopoulos struck the wrong note at the wrong time, especially when he combatively challenged someone for interrupting his speech with a honk for “another act of cowardness.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’

Over the past few years, different teams at a pair of US-based biotechs and in labs in Japan have labored to piece together a group of cancer drug programs, sharing a single corporate umbrella with research colleagues in Japan. But now their far-flung operations have been knit together into a single unit, creating a pipeline with 10 cancer drug development programs — going from early-stage right into Phase III — and a host of discovery projects managed by a collective staff of some 265 people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ear­ly-stage study

Pfizer and their partners at the mRNA specialist BioNTech have published the first glimpse of biomarker data from an early-stage study spotlighting the “robust immunogenicity” triggered by their Covid-19 vaccine, which is one of the leaders in the race to vanquish the global pandemic.

Researchers selected 45 healthy volunteers 18-55 years of age for the study. They were randomized to receive 2 doses, separated by 21 days, of 10 µg, 30 µg, or 100 µg of BNT162b1, “a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD.” Their responses were compared against the effect of a natural, presumably protective defense offered by a regular infection.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

New stan­dard of care? FDA hands Pfiz­er, Mer­ck KGaA an OK for Baven­cio in blad­der can­cer

The breakthrough therapy designation Pfizer and Merck KGaA notched for Bavencio in bladder cancer has quickly paved way for a full approval.

The PD-L1 drug is now sanctioned as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma, applicable in cases where cancer hasn’t progressed after platinum-containing chemotherapy.

Petros Grivas, the principal investigator of the supporting Phase III JAVELIN Bladder 100, called the approval “one of the most significant advances in the treatment paradigm in this setting in 30 years.”

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on hold following the death of 2 patients taking a high dose of their treatment. And there was another serious adverse event recorded in the study as well, with a total of 3 “older” patients in the study affected.

The incidents are derailing plans to file for a near-term approval, which had been expected right about now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Vac­cines will need to beat place­bo by 50% to qual­i­fy for FDA OK; UK tri­al drops Kale­tra

The FDA will set the bar for approving a Covid-19 vaccine at 50% efficacy, the Wall Street Journal reported, meaning any successful candidate will have to reduce the risk of coronavirus disease by at least half compared to placebo.

That requirement is part of guidance that the agency is set to release later today, laying out detailed criteria for vaccine developers — some of whom are eyeing an OK by the end of the year, in line with expectations at Operation Warp Speed.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Joseph Kim, Inovio CEO (Andrew Harnik, AP Images)

Pos­i­tive Covid-19 vac­cine da­ta? New mouse study? OWS in­clu­sion? Yep, but some­how, the usu­al tid­bits from In­ovio back­fire

You don’t go more than 40 years in biotech without ever getting a product to market unless you can learn the art of writing a promotional press release. And Inovio captures the prize in baiting the hook.

Tuesday morning Inovio, which has been struggling to get its Covid-19 vaccine lined up for mass manufacturing, put out a release that touched on virtually every hot button in pandemic PR.

There was, first and foremost, an interim snapshot of efficacy from their Phase I program for INO-4800.

On a roll, Mer­ck blazes through a new seg­ment of the bio­mark­er trail

Merck has notched an approval for using Keytruda to treat a biomarker-based subset of first-line colorectal cancer patients with unresectable or metastatic tumors, as the pharma giant continues to find new niches for its blockbuster PD-1 star.

The OK is significant in a number of ways. Not only does it build on an accelerated approval for all tumors characterized as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR); it also marks the first single treatment for colorectal cancer that doesn’t contain chemotherapy.